Adverse drug events (ADEs) are a significant public health problem, and they can happen in any health care setting. During transitions of care, when a patient moves from one health care setting to the next, ADEs are the cause of approximately 2 in 3 post-discharge complications. About half of these complications are preventable. To address this problem, the U.S. Department of Health and Human Services (HHS) released the National Action Plan for Adverse Drug Event Prevention (ADE Action Plan) in 2014.
Recently, HHS approved new measures for tracking ADEs, including 2020 target goals for reducing them. To expand on current efforts that aim to achieve these targets by 2020, ODPHP, AHRQ, CDC, FDA, VHA, and CMS hosted a webinar on September 28, 2017. Speakers included leaders from the 3 federal interagency workgroups representing each of the targeted drug classes (opioids, anticoagulants, and diabetes agents).
The webinar discusses:
- How and why the ADE Action Plan was created
- 2020 targets and measures
- Inpatient and outpatient data collection
- Strategies for addressing ADEs caused by each targeted drug class (opioids, anticoagulants, and diabetes agents)
- New quality payment incentives from the Centers for Medicare & Medicaid Services
We’re pleased to invite you to watch a recording of the webinar to learn more about ADEs and how to prevent them. During the webinar, subject matter experts responded to questions from participants. Check out these questions and answers to learn more about ADE data collection, changes to CMS reporting requirements, and more!
We hope you enjoy these new resources!